PACS Group, Inc.

PACS Group, Inc. (PACS) Market Cap

PACS Group, Inc. has a market capitalization of .

No quote data available.

CEO: Jason Murray

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 2024-04-11

Website: https://pacs.com

PACS Group, Inc. (PACS) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

PACS Group, Inc. operates as a holding company, primarily focused on delivering post-acute healthcare services. This encompasses operating various facilities, providing skilled professionals, and offering essential ancillary support. The company further specializes in providing a spectrum of senior living options, encompassing dedicated senior care, assisted living, and independent living residences in select communities. Founded in 2013 by Jason Murray and Mark Hancock, its corporate headquarters are located in Farmington, Utah.

Analyst Sentiment

89%
Strong Buy

From 6 Active Polls

1Y Forecast: $52.25

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$48

Median

$52

High Bound

$57

Average

$52

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$52.25
▲ +13.56% Upside
Low Target
$48.00
4% Risk
Median Target
$52.00
13% Mid
High Target
$57.00
24% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PACS GROUP INC (PACS) — Investment Overview

🧩 Business Model Overview

PACS Group provides cloud-based medical imaging workflow software—commonly positioned around picture archiving and communication system (“PACS”) functionality—paired with implementation, support, and related services. The core value chain is straightforward: PACS enables imaging data to be captured, stored, organized, and shared securely across care teams and locations, while fitting into the day-to-day workflow of dental/healthcare providers. Revenue is driven by converting practices into ongoing users of PACS infrastructure and processes, then increasing usage through additional users, storage/retention needs, and ancillary service layers (support, administration, and integration assistance).

💰 Revenue Streams & Monetisation Model

Monetisation is primarily subscription- and usage-linked, with recurring revenue tied to the installed base of imaging workstreams and the storage/retention lifecycle of patient records. Typical margin drivers include:

  • Recurring software revenue: Subscription fees for access to cloud imaging systems and ongoing service delivery.
  • Implementation/professional services: One-time onboarding, configuration, training, and integration work that supports conversion to recurring contracts.
  • Support and managed services: Ongoing support tied to uptime, workflow assistance, and compliance-oriented operations.

Over time, the model tends to favor operating leverage because once imaging data pipelines and customer workflows are established, incremental revenue can scale with comparatively limited incremental cost—provided infrastructure utilization remains efficient and customer churn stays controlled.

🧠 Competitive Advantages & Market Positioning

PACS Group’s most durable competitive moat is switching costs, reinforced by data gravity. Imaging archives are mission-critical: patient records, historical studies, and workflow configurations create high friction in migrating to alternative systems. Competitors may offer attractive feature sets, but replacing years of organized imaging history, integrations, and operational routines is expensive in time, training, and risk.

Additional advantages often come from intangible assets—software know-how, secure handling of health data, operational process maturity, and integration experience that reduces deployment uncertainty for new practices.

  • Carestream Dental: Broad dental imaging and IT offerings with strong distribution and product depth; typically competes across hardware + enterprise imaging stacks.
  • DEXIS (Midmark): Focused on dental imaging solutions; often emphasizes point-of-care imaging and integrated device ecosystems.
  • Philips / Agfa HealthCare (enterprise radiology PACS ecosystem): Enterprise radiology IT incumbents with large-scale deployments.

Industry focus contrast: PACS Group generally targets the practical needs of providers managing ongoing imaging workflows with an emphasis on cloud delivery and operational continuity. Enterprise incumbents frequently compete on large-network scale and broader enterprise IT budgets, while device-centric dental players often compete on hardware and narrower imaging touchpoints. PACS Group’s differentiation is more tied to embedding into recurring clinical workflows and retaining customers through data and process integration.

🚀 Multi-Year Growth Drivers

A 5–10 year horizon supports several structural growth vectors:

  • Digitization and cloud migration: Continued movement away from siloed or legacy storage toward centralized, accessible imaging archives.
  • Workflow standardization: Practices and multi-location groups increasingly need uniform imaging processes, consistent retention policies, and efficient sharing.
  • Rising data volume and retention requirements: More imaging frequency and longer retention windows increase demand for storage, organization, and access.
  • Integration into care delivery: As imaging becomes a shared input to downstream diagnostics and treatment decisions, demand for secure interoperability rises.
  • Optionality from analytics and automation: Once imaging data is organized and accessible through a platform, incremental capabilities (quality assurance, reporting support, and workflow automation) can be layered over the installed base.

Collectively, these drivers expand the addressable market and support monetisation expansion per customer through retention, additional users, and higher storage needs.

⚠ Risk Factors to Monitor

  • Cybersecurity and data privacy exposure: Imaging platforms handle sensitive health information; breaches or service compromises can impair trust and trigger regulatory consequences.
  • Regulatory and compliance obligations: HIPAA and related state/federal requirements elevate the cost and complexity of maintaining compliant operations.
  • Concentration of customer spend and procurement cycles: Practice economics and IT budget timing can affect new customer conversions and expansion.
  • Integration complexity: Success depends on interoperability with existing workflows (device, practice management, and clinical systems). Integration failures can increase churn risk.
  • Competitive pricing pressure: Larger incumbents may bundle or cross-subsidize; maintaining durable differentiation requires continued product and operational execution.
  • Infrastructure and reliability: Uptime, performance, and disaster recovery must remain consistent as data volumes grow.

📊 Valuation & Market View

Equity markets typically value healthcare IT software using a blend of EV/EBITDA-style frameworks and P/S or enterprise-value-to-growth signals, with outcomes largely driven by SaaS-like fundamentals:

  • Revenue quality: The proportion of recurring revenue and the stability of the installed base.
  • Retention and churn: Imaging-data switching costs can support durability, but measured outcomes are essential.
  • Gross margin trajectory: Infrastructure scale and support efficiency impact long-run profitability.
  • Operating leverage: Ability to grow without proportional growth in sales and support costs.
  • Cash conversion: The relationship between accounting earnings and free cash flow.

For this sector, the valuation multiple tends to expand when investors gain confidence in durable recurring revenue, improved unit economics, and predictable scaling of customer growth.

🔍 Investment Takeaway

PACS Group’s investment case rests on a defensible software switching-cost profile: imaging archives and clinical workflow integrations create meaningful data gravity that makes customer churn less straightforward than in typical application software. When combined with continued cloud adoption, rising imaging data volume, and workflow digitization across dental and healthcare settings, the platform can sustain multi-year growth while offering the potential for operating leverage as recurring revenue scales. The key diligence focus should be customer retention, security/compliance performance, and the success rate of integrations that preserve the installed base’s value.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"PACS reported Q1’26 (ended 2026-03-31) revenue of $1.42B and net income of $80.7M, with EPS of $0.51. Sequentially (QoQ), revenue rose 4.6% (from $1.36B in 2025-12-31) and net income increased 35.2% (from $59.7M). Year-over-year (YoY), revenue grew 11.1% (from $1.28B in 2025-03-31) and net income surged 183.4% (from $28.5M), indicating strong operating leverage. Margins improved over the quarter: gross margin expanded to 24.4% (from 23.5% in Q4’25), and net margin rose to 5.7% (from 4.4% in Q4’25). On a YoY basis, net margin also widened materially (from 2.2% in Q1’25). Operating income increased to $120.0M and operating margin climbed to 8.5%. Cash flow also strengthened: operating cash flow was $236.3M and free cash flow was $214.5M in Q1’26. Balance-sheet resilience appears mixed: leverage remains high with total assets up to $5.66B and stockholders’ equity at $1.04B, but net debt is elevated (~$2.85B). Total shareholder returns look very strong given price momentum: the stock is up 286% over the last year versus a $0 dividend yield and no buybacks reported in Q1’26. Analyst valuation context shows a consensus target (~$44.67) below the current $35.2 figure, suggesting the near-term upside case is more sentiment/momentum than valuation."

Revenue Growth

Good

QoQ revenue up 4.6% (1.36B -> 1.42B). YoY revenue up 11.1% (1.28B -> 1.42B), with acceleration across the 4-quarter strip.

Profitability

Strong

Net income up 35.2% QoQ and 183.4% YoY. Net margin improved to 5.7% in Q1’26 (vs 4.4% in Q4’25 and 2.2% in Q1’25), indicating expanding profitability.

Cash Flow Quality

Good

Q1’26 operating cash flow was $236.3M and free cash flow $214.5M, supporting the earnings recovery. No dividends paid in the quarter; buybacks are not indicated for Q1’26.

Leverage & Balance Sheet

Neutral

Total assets increased to $5.66B and equity improved to $1.04B, but leverage remains high (total debt $3.10B; net debt ~$2.85B). Liquidity is slightly tight (current ratio ~1.00).

Shareholder Returns

Strong

Price momentum is exceptional: +286.4% 1Y. Dividend yield is ~0 in Q1’26, and buybacks are not evident in the quarter; total return is driven primarily by capital appreciation.

Analyst Sentiment & Valuation

Positive

Consensus target ($44.67) implies value above the provided current price context ($35.2), but valuation multiples remain elevated (e.g., trailing P/E ~15.6 per provided ratios). Sentiment likely outweighs near-term fundamental re-rating.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

So what: PACS started 2026 with broad-based operating momentum and upgraded profitability expectations. Q1 revenue grew 11% to $1.42B and diluted EPS rose to $0.50 from $0.17, while adjusted EBITDA climbed 75% to $170.4M. The quarter included ~$16.3M from California W Equip quality/workforce payments that were excluded from initial guidance, but management also emphasized underlying KPI strength: same-store revenue +8%, total occupancy 90.9% vs 89.2% prior year, and skilled mix up 90 bps to 30.5%. Management raised 2026 adjusted EBITDA guidance by $50M at all levels to $605M–$625M and reaffirmed revenue at $5.65B–$5.75B, refining methodology to exclude future acquisitions (previously ~$120M revenue). Q&A focused on reimbursement dynamics, particularly quality incentive program timing (no guidance) and managed care gains driven by admissions growth plus contract renegotiations. Overall, visibility improved on organic operating performance, while payment timing and investigations remain key uncertainties.

AI IconGrowth Catalysts

  • Maturation progression across ramping facilities drove stronger occupancy and skilled mix (ramping cohort improving toward mature performance levels)
  • Same-store basis momentum: occupancy improvement from 89.6% to 90.8% and skilled mix gains underpinning 8% same-store revenue growth
  • Quality/clinical consistency scale-up: CMS 4- or 5-star facilities increased to 222 from 207 year-end 2025

Business Development

  • SEIU referenced as a key California labor-union relationship with meaningful discussions on workforce positioning
  • Managed care plan renegotiations referenced broadly as “hundreds of contracts” (no specific plan names provided)

AI IconFinancial Highlights

  • Revenue: $1.42B (+11% YoY)
  • Net income: $80.7M (up $52.3M from $28.5M in Q1 2025)
  • Adjusted EBITDA: $170.4M (+75% YoY; +$72.8M)
  • Adjusted EBITDAR: $265.9M
  • Diluted EPS: $0.50 vs $0.17 prior year
  • Adjusted EBITDA included ~$16.3M net benefit from California W Equip workforce and quality incentive payments (not included in original guidance)
  • Cost of services: $1.07B (+5% YoY) supporting operating leverage vs 11% revenue growth
  • Same-store revenue: +8% YoY; total occupancy 90.9% vs 89.2% prior year
  • Skilled mix: 30.5% (+90 bps YoY)
  • Guidance change: 2026 adjusted EBITDA raised to $605M–$625M (up $50M at all levels vs prior guidance); midpoint implies ~22% growth over 2025
  • Guidance methodology refinement: future acquisitions removed from 2026 guidance (previously included ~$120M revenue tied to future acquisitions)

AI IconCapital Funding

  • Share repurchase authorization: $250M approved by the Board; timing/magnitude opportunistic, open-market repurchases during permitted windows
  • No intention to implement 10b5-1, accelerated repurchase, or similar structures at this time
  • Available liquidity: ~$800M (including ~$250M cash)
  • Net leverage: ~0.1x
  • Strategic real estate investments: $86.5M deployed during the quarter

AI IconStrategy & Ops

  • Operational model: locally led, centrally supported execution; facility leaders empowered at point of care with PACS services providing systems/compliance support
  • Integration/transition pipeline: 40 AITs in the administrator and training program as an indicator of scalable leadership bench
  • Special focus turnaround example (Arizona facility): reduced special focus survey deficiencies from >20 to fewer than 5 and graduated from program; maintained occupancy above 90%
  • Added same-store reporting for 1Q 2026 to improve visibility into underlying portfolio health

AI IconMarket Outlook

  • 2026 revenue guidance reaffirmed: $5.65B–$5.75B
  • 2026 adjusted EBITDA guidance increased: $605M–$625M
  • No guidance provided for quality incentive payments due to timing/amount uncertainty; specifically: California W Equip successor uncertainty remains and future payments expected but excluded from guidance

AI IconRisks & Headwinds

  • Managed care provider admission reduction concern discussed by market; company stated it has not observed impacts to admissions trends or skilled mix in Q1
  • Quality incentive payment timing uncertainty persists (California W Equip and analogous programs); future payments expected but not included in guidance
  • Government investigation process ongoing; company unable to estimate timing of resolution
  • Material weaknesses remediation ongoing (internal control of financial reporting), expecting substantial progress in 2026

Q&A: Analyst Interest

  • Topic: California/Ohio quality incentive programs—payment timing and how to think about rate moves. Management described Ohio quality program performance as strong across long-tenured and newly acquired facilities, emphasizing active state discussions on payout timing. They reiterated no guidance for quality payments due to unpredictability, and highlighted ongoing advocacy for quality-linked reimbursement and rate stability.
  • Topic: 2026 outlook mechanics—embedded assumptions across cohorts and the impact of removing future acquisitions. Management stated revenue guidance was unchanged because Q1 showed strong KPI performance (occupancy, skilled mix, reimbursement rates) particularly in the ramping cohort. They confirmed guidance excludes future acquisitions (previously ~$120M revenue) and excluded quality incentive payments due to difficult-to-estimate timing and amounts.
  • Topic: Managed care reimbursement growth—what drove 1Q PPD trends. Management attributed managed care strength to both rising census/admissions and renegotiations of “hundreds” of contracts, pairing quality/outcomes with appropriate reimbursement and acuity support. They suggested continued managed care census growth and further reimbursement strength, given their role in post-acute cost-effective care delivery.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the PACS Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — PACS Group, Inc. (PACS) Financial Profile